Both serous endometrial and serous ovarian cancers exhibit extremely high rates of mutations in the tumor suppressor gene, TP53 (90% of serous endometrial carcinomas [2], 96% of serous ovarian carcinomas [3]). Here, TP53 is linked to ovarian serous adenocarcinoma.